Report Highlights

U.S. Nano therapy Market Overview

The U.S. nano therapy market reached USD 3.8 billion in 2024 and is projected to reach USD 9.2 billion by 2032 at an 11.7% CAGR, driven by the maturation of lipid nanoparticle technology following COVID-19 vaccine deployment, the growing pipeline of FDA-approved nano-formulated therapeutics across oncology, rare disease, and infectious disease indications, and the expanding application of nanotechnology to drug delivery problems — including CNS penetration, targeted tumour delivery, and extended-release formulation — that conventional drug delivery approaches cannot solve efficiently. Nano therapy encompasses a broad range of nano-scale therapeutic platforms including lipid nanoparticles, polymeric nanoparticles, dendrimers, gold nanoparticles, iron oxide nanoparticles, and carbon nanotubes, each with distinct delivery mechanism advantages suited to specific therapeutic applications and clinical contexts.

The U.S. market benefits from the world's most advanced nano therapy research infrastructure — anchored by NCI-funded nanotechnology programmes, NIH Nanomedicine Development Centre grants, and the concentration of nano therapy biotechnology companies in the Boston-Cambridge corridor, San Francisco Bay Area, and San Diego biotech clusters. FDA's Nanotechnology Task Force and the agency's guidance framework for nano-scale drug products — including the 2018 guidance on drug products with nano-scale components — provide the regulatory framework that guides nano therapy product characterisation and clinical development in the U.S. market, creating a relatively navigable regulatory environment compared to markets where nano therapy regulatory guidance is less developed.

Growth Drivers for U.S. Nano therapy Market

Three demand drivers sustain the U.S. nano therapy market's growth through 2032. The personalised cancer vaccine opportunity — where LNP-delivered mRNA encoding patient-specific tumour neoantigens is being developed as individualised cancer immunotherapy — represents the most commercially transformative nano therapy application in the current pipeline. BioNTech's BNT111 and mRNA-4157 (V940) in collaboration with Merck have demonstrated early clinical signals that mRNA-encoded personalised cancer vaccines combined with pembrolizumab improve outcomes in high-risk resected melanoma, generating Phase III trial investment that will produce the pivotal data supporting regulatory submission within the 2025–2028 period. If personalised cancer vaccines achieve FDA approval, each patient's vaccine requiring custom LNP-formulated mRNA synthesis would represent the highest per-patient nano therapy revenue in the field's commercial history.

The RNA interference therapeutics market — which delivers small interfering RNA using LNP or GalNAc conjugate delivery systems to silence disease-causing gene expression in the liver — has established commercial proof of concept through Alnylam Pharmaceuticals' FDA-approved products including Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran), and Leqvio (inclisiran). The siRNA therapeutic pipeline's expansion from rare hepatic diseases to cardiometabolic, neurological, and oncology applications — all enabled by nano-scale delivery systems — is creating a growing commercial market for LNP and alternative nano delivery platforms whose revenue potential extends well beyond the rare disease orphan drug market that defined the field's initial commercial phase. CRISPR gene editing delivery — which requires nano-scale vehicles to efficiently deliver Cas9 protein or mRNA and guide RNA into target cells without triggering immune responses or off-target genomic modifications — is the most technically demanding and commercially promising emerging application for nano therapy delivery technology.

Regulatory and Reimbursement Environment

The U.S. nano therapy regulatory framework is administered through FDA's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, with nano-scale drug product characterisation requirements established through the 2018 guidance on drug products with nano-scale components. Nano-formulated drug products are regulated as drug products or biologics according to their primary mode of action — an LNP-formulated mRNA therapeutic is regulated as a biologic under BLA framework, while an LNP-formulated small molecule chemotherapy reformulation is regulated as an NDA drug product. FDA's Critical Path Initiative includes nano-scale drug delivery as a priority area for regulatory science development, and the Nanotechnology Task Force's ongoing work is progressively clarifying characterisation requirements for novel nano delivery systems that did not have established regulatory precedent before the COVID-19 LNP vaccine approvals created new FDA reviewer expertise and analytical method precedents.

Reimbursement for approved nano therapy products operates through the standard drug and biologic reimbursement frameworks — Medicare Part B for physician-administered products, Medicare Part D for self-administered products, and hospital formulary inclusion for inpatient administration. Nano-formulated cancer chemotherapy products — Doxil, Abraxane, and Onivyde — are reimbursed through Medicare Part B oncology drug reimbursement at average sales price plus 6%, a reimbursement structure that supports premium pricing for nano-formulated equivalents of conventional chemotherapy agents when the nano formulation demonstrates clinically meaningful toxicity reduction or efficacy improvement over conventional equivalents. The personalised cancer vaccine segment will require novel reimbursement frameworks that CMS does not yet have established pathways for, as each patient's individualised mRNA synthesis represents a unique manufacturing run rather than a standardised product — creating a reimbursement model development challenge that will require negotiation between manufacturers, payers, and CMS before personalised cancer vaccines can achieve broad commercial access.

Market Opportunities in U.S. Nano therapy Market

The CNS disease nano therapy opportunity addresses the blood-brain barrier penetration challenge that has historically limited effective drug delivery to central nervous system diseases — Alzheimer's disease, Parkinson's disease, brain cancers, and neuroinflammatory conditions. Nano-scale delivery systems — specifically lipid nanoparticles with surface modifications enabling receptor-mediated transcytosis across the BBB, polymeric nanoparticles with apolipoprotein E coating enabling LDL receptor-mediated brain uptake, and exosome-based delivery vehicles with natural brain-homing properties — are demonstrating preclinical BBB penetration efficiencies that are advancing toward Phase I clinical evaluation for CNS indications where no oral or injectable conventional small molecule equivalent can achieve therapeutic brain concentrations. FDA's Breakthrough Therapy and Fast Track designations for CNS nano therapy programmes — recognising the unmet need in neurological diseases — are compressing development timelines and creating a regulatory support environment for CNS nano therapy that accelerates the typically extended CNS drug development timelines.

The iron oxide nanoparticle opportunity for magnetic resonance imaging contrast enhancement and magnetic hyperthermia cancer treatment represents a clinically mature nano therapy application with established safety precedent. FDA-approved iron oxide nanoparticle contrast agents — including ferumoxytol (Feraheme) — demonstrate the regulatory pathway for iron oxide nanoparticle products, and the adaptation of iron oxide nanoparticles for magnetic hyperthermia — where iron oxide particles accumulated in tumours generate heat when exposed to alternating magnetic fields, selectively destroying tumour tissue — is in Phase II clinical evaluation at several U.S. academic medical centres. MagForce's iron oxide magnetic hyperthermia system for glioblastoma has achieved European CE mark and is in FDA approval pathway discussions, potentially providing the U.S. market's first magnetic hyperthermia nano therapy product within the forecast period.

Market at a Glance

Leading Market Participants

• Moderna
• Alnylam Pharmaceuticals
• BioNTech (U.S. operations)
• Merck (mRNA-4157 partnership)
• Arrowhead Pharmaceuticals
• Arctus Biotherapeutics
• Precision BioSciences
• Nuvation Bio
• Sorrento Therapeutics
• Corcept Therapeutics (nanoparticle programmes)

Competitive Outlook for U.S. Nano therapy Market

The U.S. nano therapy market will reach USD 9.2 billion by 2032, with LNP technology maintaining its dominant platform position while specialist nano delivery systems — GalNAc conjugates for liver-targeted siRNA, CNS-penetrating nanoparticles for neurological applications, and iron oxide particles for imaging and hyperthermia — establish commercially significant niches in indications where LNP does not provide optimal delivery efficiency. The personalised cancer vaccine market — if Phase III clinical trial data from BioNTech and Moderna programmes supports FDA approval by 2027–2028 — would transform the U.S. nano therapy market's revenue trajectory by adding a per-patient revenue category an order of magnitude above existing nano therapy pricing for the same patient population. The CRISPR delivery market — where the successful clinical demonstration of in vivo LNP-mediated CRISPR gene editing in hepatic targets creates the precedent for CNS, ocular, and oncology CRISPR applications — will be the most commercially significant nano therapy technology development after personalised cancer vaccines in determining which platforms and companies define the U.S. nano therapy market's competitive structure through 2035.

The most commercially vulnerable position in the nano therapy market is companies with LNP manufacturing capability but without differentiated formulation expertise or preferred application focus — as LNP manufacturing capacity has expanded significantly since 2020 and commodity LNP formulation services are increasingly available from CDMOs including Precision NanoSystems (now Cytiva) and Evonik Industries. Nano therapy companies who will sustain premium commercial positions are those with proprietary LNP formulation improvements — ionisable lipid chemistry, surface modification patents, targeting ligand integration — or with established clinical precedents in specific therapeutic areas that create regulatory and manufacturing experience barriers against generic nano therapy entrants who lack the characterisation expertise and regulatory precedent accumulated through years of clinical programme development.